

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		<i>Complete if Known</i>			
		Application Number	10/731,690		
		Filing Date	December 8, 2003		
		First Named Inventor	Nurulain ZAVERI et al.		
		Art Unit	1654		
		Examiner Name	Unassigned		
Sheet	1	of	1	Attorney Docket Number	8500-0269.20

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.	Document No.	Issue Date or Publication Date	Name of Patentee or Applicant of Cited Document	Class	Subclass	Filing Date if Appropriate
2nd	AA	4,237,162	12/2/80	Kabbe et al.			
2nd	AB	6,410,061	6/25/02	Morré et al.			

OTHER DOCUMENTS — NONPATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), Title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T	
2nd	AC	HIROSE et al. (1997), "Effects of Greent Tea Catechins on the Progression or Late Promotion Stage of Mammary Gland Carcinogenesis in Female Sprague-Dawley Rats Pretreated with 7,12-Dimethylbenz(a)Anthracene," <i>Cancer Letters</i> 112:141-147.		
2nd	AD	LI et al. (2000), "Enantioselective Synthesis of Epigallocatechin-3-Gallate (EGCG), the Active Polyphenol Component from Green Tea," <i>Organic Letters</i> 3(5):739-741.		
2nd	AE	MUKHTAR et al. (1999), "Green Tea in Chemoprevention of Cancer," <i>Toxicological Science</i> 52(Supplement):111-117.		
2nd	AF	ZAVERI (2001), "Synthesis of a 3,4,5-Trimethoxybenzoyl Ester Analogue of Epigallocatechin-3-Gallate (EGCG): A Potential Route to the Natural Product Green Tea Catechin, EGCG," <i>Organic Letters</i> 3(6):843-846.		

Examiner Signature	<i>Lina Davis</i>	Date Considered	12/1/2005
--------------------	-------------------	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/731,690
Filing Date	December 8, 2003
First Named Inventor	Nurulain ZAVERI et al.
Art Unit	1654/625
Examiner Name	Unassigned Z. DAVIS
Attorney Docket Number	8500-0269.20

U.S. PATENT DOCUMENT

Examiner Initials*	Cite No.	Document No.	Issue Date or Publication Date	Name of Patentee or Applicant of Cited Document	Class	Subclass	Filing Date if Appropriate
md	AG	2002/0151582	10/17/02	Dou et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document No.	Publication Date	Country	Class	Subclass	T
md	AH	JP 2001-253879	9/18/01	Japan			
md	AI	WO 99/22728	5/14/99	PCT			*

OTHER DOCUMENTS — NONPATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), Title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
md	AJ	Derwent database WPI, AN 2002-307970, XP-002284951, English abstract for JP 2001-253879.	*
md	AK	HASHIMOTO et al. (1996), "Evaluation of Tea Polyphenols as Anti-HIV Agents," <i>Bioorganic & Medicinal Chemistry Letters</i> 6(6):695-700.	
md	AL	UESATO et al. (2000), "Antitumor Promoting Activities of 3-O-Acyl-(-)-Epigallocatechins," <i>Bioorganic & Medicinal Chemistry Letters</i> 10:1673-1675.	

*Abstract only


Examiner Signature	<i>Lina W Davis</i>	Date Considered	12/1/2005
--------------------	---------------------	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)



Complete if Known

Sheet	1	of	1	Application Number	10/731,690
				Filing Date	December 8, 2003
				First Named Inventor	Nurulain ZAVERI et al.
				Art Unit	4654 / 625
				Examiner Name	Unassigned ZND/NLS
				Attorney Docket Number	8500-0269.20

OTHER DOCUMENTS — NONPATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), Title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
gnd	AM	Chemical Abstracts Service database CAPLUS, AN 1969:36948, DN 70:36948, RN:802-38-0, CLARK-LEWIS (1968), "Flavan Derivatives. XXV. Mass Spectra of 3-Hydroxyflavanones, Flavan -3-ols, and Flavan-3,4-diols," Australian Journal of Chemistry 21(12):3025-3054 (abstract only).	*
gnd	AN	LEE al. (1992), "Flavan-3-ol Gallates and Proanthocyanidins from Pithecellobium Lobatum," <i>Phytochemistry</i> 31(6):2117-2120.	
gnd	AO	WEINGES (1964), "The Occurrence of Catechins in Fruits," <i>Phytochemistry</i> 3:263-266.	
gnd	AP	ZHU et al. (2001), "Study of Tea Polyphenol as a Reversal Agent for Carcinoma Cell Lines' Multidrug Resistance (Study of TP as a MDR Reversal Agent," <i>Nuclear Medicine and Biology</i> 28:735-740.	

Examiner Signature	<i>Linn W Davis</i>	Date Considered	12/1/2005
--------------------	---------------------	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.